Member Info for Shrek1st

Might be an idea for Trev to let the market know what the clinical and regulatory strategy is?

Maybe an interview to flesh it out and inform us?

Being serious for a moment, they previously said that the company was meeting with the FDA in Q2 regarding phase 2. We are due an update on that at least.

Shrek

Hello all,

Found this 4 minute interview with Dr Connelly.

https://open.spotify.com/episode/5sYGtavz6UFAWznXRJ1t92?si=cAxnczmoQvCB2U_b6uiqPA

Shrek

The EAP gets a mention from the UNC:

https://endeavors.unc.edu/trial-and-discovery/

“We also have an expanded access program for patients who have exhausted available treatments. They will try a new oral therapy called gallium maltolate, which has proven effective for patients with various cancers”.

Shrek

Morning all,

To facilitate a phase 2, adequately fund product development and cover running costs will require more working capital. The accounts do not show a ‘step change’ in revenue as previously alluded to. Hopefully the necessary capital will be provided by a partner that will allow the company to grow and successfully commercialise the potential offered. Maybe Semantic would like to discuss this?

Shrek

Good afternoon

The study record shows an update.

https://clinicaltrials.gov/study/NCT04319276

Shrek

If anyone missed the webinar before, this link takes you to a recording

https://youtu.be/PYFAJ_fc79g

Shrek

Https://x.com/almusella/status/1899229326932951044?s=46&t=U7xny3m_YwAtHvYTKn00XA

Webinar Tue 3/11/25 1pm ET on Gallium Maltolate, an experimental oral drug for recurrent glioblastoma. Join a doc running the trial & a patient to learn about its unique action & Expanded Access Program. Free event: virtualtrials.org/webinar

#gbm

Shrek

Good morning,

This article is about GE healthcare and the European Society of Radiology strengthening their relationship. The next meeting is the ECR in Vienna at the end of this month.

GE healthcare have also announced an investment of $138 million in contrast media manufacturing in Ireland.

This is the link to the article:

https://www.myesr.org/ge-healthcare-strengthens-alliance-with-esr-as-platinum-supporter-for-ecr-2025/

There is nothing directly attributable to IB, however the focus on AI solutions is clear.

“Elie Chaillot, President and CEO of GE HealthCare International, added “We are excited to continue our collaboration with the European Society of Radiology for ECR 2025. Our commitment to enabling precision care drives everything we do. This year we are proud to showcase over 40 AI-enabled innovations designed to enable timely, accurate diagnoses, support personalized care decisions, and streamline clinical workflows. By integrating advanced technologies and sustainable practices, we aim to provide more precise, personalized, and environmentally conscious patient care and make healthcare more outcome-driven and efficient.”

Good weekend all,

Shrek

Thanks Max,

That is almost a full house presenting. Very impressive.

Cheers

Shrek

😁 Hi Max,

I haven’t been able to find anything on that November seminar. We should get some coverage of the next one though.

GE Healthcare are attending the European Congress of Radiology next month in Vienna. Their website is good if anyone is interested.

I haven’t found anything specifically for the company but I thought these two entries were interesting:

February 26, 2025 - February 27, 2025 | 11:00 CET | Level 0, Area F, GE HealthCare booth

Unveiling the future of MRI at ECR

Save the date

Are you ready to discover our latest MR innovation? Join us on Wednesday, February 26 and Thursday, February 27 at 11:00 am

Not all products and solutions, shown on the GE HealthCare Events Center, may be available in your country.

And then this one

February 26, 2025 - March 1, 2025 | 10:00-17:00 | Level 0, Area F, Room 0.91

Come and co-create the future of imaging

Save the date

How can new approaches to scanning enable future-proof workflows that increase the departments' efficiency? Explore with us the root causes for delays and inefficiencies and ideate together on possible improvements.

Join this session to imagine the future of imaging. Participants will be required to sign an NDA.

Daily session Wednesday 26th February — Saturday 1st March.

Reach out to your local sales representative to reserve a slot.

GE HealthCare Team

Have a good weekend

Shrek

Thanks Max,

Do you remember this seminar from Casey Zoss from November last year? I couldn’t find any information on it so it will be interesting to see this new presentation.

Gallium Maltolate for Treatment of Glioblastoma: Bench to Bedside and Back Again

Presenter: Casey Zoss, Graduate Student

Schmainda Lab, Department of Biophysics, Medical College of Wisconsin

Event Location Biophysics Conference Room (MFRC 2063)

Good weekend all

Cheers

Shrek

No worries, I wish I was somewhere warmer! Just an early start on a job.

Did you watch the question and answer session at the end? Very impressive if this all works as they think.

Shrek

Hi Dmac

Exactly! I don’t think people have watched the video.

Shrek

I need to watch it again when I have time later, however I was impressed with the hot off the press news and her answer when asked how long this would mean- “years”.

Just need a partner now.

Cheers

Shrek

Good morning,

Link to the video of yesterday’s webinar.

https://www.youtube.com/watch?v=UZYy02X7zJY

Shrek

Thanks Max,

I am looking forward to the webinar and hopefully we will all find out more about the progress of Gam. The roadmap should be interesting.

This is the information from the registration page:

Gallium Maltolate - New Directions for Cancer Therapy

21 January 2025 • 18:00 - 19:00

Online

Share this event

Details

Join us for a webinar exploring the potential of Gallium Maltolate in cancer therapy. This innovative metallodrug has shown promise in targeting a variety of cancers, including brain tumors such as Glioblastoma and pediatric high-grade Gliomas.

In this session, you’ll learn:

The science behind Gallium Maltolate and its unique mechanism of action.

Insights from preclinical studies and advancements in animal models.

Current clinical trials and the roadmap for future therapeutic applications.

Speakers (1)

Mona Al-Gizawiy, PhD.

Assistant Professor

The Medical College of Wisconsin

Cheers

Shrek

Good morning all,

This is an article written by Roland Rott, who is the chief imaging officer at GE HealthCare.

It is a good read and he is positive on the role of AI. Here is the link:

https://www.auntminnie.com/imaging-informatics/artificial-intelligence/article/15712005/ge-healthcare-ai-will-transform-early-cancer-detection-save-lives-in-2025

He outlines the benefits of AI in the fight against cancer.

“The rapid maturation of AI-powered medical imaging technology leaves me bullish that 2025 will be remembered as a watershed year in the global fight against cancer as we see more radiologists and oncologists equip themselves with the high-tech tools of tomorrow to deliver higher-quality care today”.

Well worth a read.

Cheers

Shrek

Fingers crossed 🤞

Dr Musella is a welcome addition to the company. Found this posted on facebook:

MUSELLA FOUNDATION IS OFFERING FUNDS TO HELP PATIENTS ENROLL IN THE EXPANDED ACCESS PROGRAM FOR RECURRING GLIOBLASTOMA.

End Brain Cancer Initiative - the Chris Elliot fund

7 Jan • O

Timeline photos

Hope is here!

The Musella Foundation is offering funds to help patients enroll in the Expanded Access Program (EAP) for recurring Glioblastoma.

The EAP - often called 'compassionate use' - provides a lifeline for patients by offering experimental treatments outside of clinical trials.

With FDA oversight, this program enables access to therapies that could change lives for those with limited treatment options.

For details, visit https://ecs.page.link/S6XAP or email eap@imagingbiometrics.com.

Cheers

Shrek

Thanks Max,

I like the bit about the paediatric phase 1.

Cheers

Shrek

This is from the RSNA

https://pubs.rsna.org/doi/10.1148/rycan.249026

“• Impact: Single-dose LFA DSC MRI is a promising tool for glioblastoma monitoring and treatment planning. With further validation against histopathologic data, this approach could play an integral role in clinical decision-making.”

Shrek